Skip Nav Destination
Issues
1 February 2001
ISSN 1078-0432
EISSN 1557-3265
Editorial
Clinical Trials
Phase I and Pharmacokinetic Study of Ecteinascidin 743 Administered as a 72-Hour Continuous Intravenous Infusion in Patients with Solid Malignancies1
David P. Ryan; Jeffrey G. Supko; J. Paul Eder; Michael V. Seiden; George Demetri; Thomas J. Lynch; Alan J. Fischman; John Davis; Jose Jimeno; Jeffrey W. Clark
Molecular Oncology, Markers, Clinical Correlates
Experimental Therapeutics, Preclinical Pharmacology
Combination of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Actinomycin D Induces Apoptosis Even in TRAIL-resistant Human Pancreatic Cancer Cells1
Hosei Matsuzaki; Bruno M. Schmied; Alexis Ulrich; Jens Standop; Matthias B. Schneider; Surinder K. Batra; Kathleen S. Picha; Parviz M. Pour
Cancer Biology, Immunology, Cytokines
Letter to the Editor
Correspondence re: C. F. M. Sier et al., Enhanced Urinary Gelatinase Activities (Matrix Metalloproteinases 2 and 9) Are Associated with Early-Stage Bladder Carcinoma: A Comparison with Clinically Used Tumor Markers. Clin. Cancer Res., 6: 2333–2340, 2000.1
Susanne Gerhards; Frank Koenig; Dmitri Daniltchenko; Steffen Hauptmann; Dietmar Schnorr; Stefan A. Loening
Advertisement